Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Titel:
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Auteur:
Schachter, Jacob Ribas, Antoni Long, Georgina V Arance, Ana Grob, Jean-Jacques Mortier, Laurent Daud, Adil Carlino, Matteo S McNeil, Catriona Lotem, Michal Larkin, James Lorigan, Paul Neyns, Bart Blank, Christian Petrella, Teresa M Hamid, Omid Zhou, Honghong Ebbinghaus, Scot Ibrahim, Nageatte Robert, Caroline